In response to comment on "Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand?" by Jara LJ et al
| dc.contributor.author | Jara, Luis Javier | |
| dc.contributor.author | Vera-Lastra, Olga | |
| dc.contributor.author | Mahroum, Naim | |
| dc.contributor.author | Pineda, Carlos | |
| dc.contributor.author | Shoenfeld, Yehuda | |
| dc.date.accessioned | 2022-11-23T09:32:36Z | |
| dc.date.available | 2022-11-23T09:32:36Z | |
| dc.date.issued | 2022 | |
| dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.description.abstract | We thank Dr. Kunal Chandwar for their interest in our article “Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/infammatory syndrome expand?” Indeed, we have included all of the COVID-19 vaccines, and we agree with you that they have diferent mechanisms of action but similar capabilities to protect against COVID19 to millions of people. Therefore, they also can induce adverse effects, including autoimmune syndromes, in a minority of people with genetic and environmental risk factors. | |
| dc.identifier.citation | Jara, L. J., Vera-Lastra, O., Mahroum, N., Pineda, C. ve Shoenfeld, Y. (2022). In response to comment on "Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand?" by Jara LJ et al. Clinical Rheumatology, 41(9), 2921-2922. https://doi.org/10.1007/s10067-022-06249-1 | |
| dc.identifier.doi | 10.1007/s10067-022-06249-1 | |
| dc.identifier.endpage | 2922 | |
| dc.identifier.issn | 0770-3198 | |
| dc.identifier.issn | 1434-9949 | |
| dc.identifier.issue | 9 | |
| dc.identifier.pmid | 35852775 | |
| dc.identifier.scopus | 2-s2.0-85134491662 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 2921 | |
| dc.identifier.uri | https://doi.org/10.1007/s10067-022-06249-1 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/10016 | |
| dc.identifier.volume | 41 | |
| dc.identifier.wos | 000827388700006 | en_US |
| dc.identifier.wosquality | Q3 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Mahroum, Naim | |
| dc.language.iso | en | |
| dc.publisher | Springer London Ltd | |
| dc.relation.ispartof | Clinical Rheumatology | en_US |
| dc.relation.publicationcategory | Diğer | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Autoimmune Post?COVID | |
| dc.subject | Vaccine Syndromes | |
| dc.subject | COVID | |
| dc.title | In response to comment on "Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand?" by Jara LJ et al | |
| dc.type | Letter |
